Creative Biolabs develops antibody-lectin sandwich research assays with orientation-aware reagent pairing, background control, matrix assessment, and transparent glycoform interpretation across comparative research studies.
Creative Biolabs develops research assays for teams that need to ask whether a defined glycan feature is present on a defined protein target. Our antibody-lectin sandwich research assay development service sits within Anti-Glycan Antibody Research Services and can begin from an existing immunoassay, target protein, candidate antibody, candidate lectin, or project-specific sample matrix.
The assay is most useful when total protein abundance alone does not answer the research question. An antibody provides target identity, while a lectin contributes sensitivity to a defined carbohydrate motif. That combination can reveal relative glycoform differences, but only when reagent-derived glycans, blocking materials, epitope accessibility, and matrix interference are addressed during development.
Capture antibodies are glycoproteins, many common blockers contain glycan-bearing proteins, and lectins recognize families of structures rather than a single molecular species. As a result, a strong signal can arise from the captured target, the capture reagent, the blocker, other matrix glycoproteins, or a combination of these sources. Specialized design is needed to assign the signal with reasonable confidence.
Development is organized around feasibility, reagent pairing, assay orientation, background reduction, matrix behavior, and the intended research comparison. Creative Biolabs can adapt the depth of work from an early feasibility study to a more developed research protocol with documented conditions and pilot sample data. Exact scope depends on the starting reagents and how much analytical confidence the downstream study requires.
Candidate antibodies and lectins are assessed as functional pairs, not as independent high-performing reagents. The antibody needs to capture the target without blocking the glycan region of interest, while the lectin needs to respond to the relevant feature while maintaining manageable background. Detection labels, secondary reagents, plate chemistry, and incubation order are reviewed as part of the pair.
Controls may include target-negative material, deglycosylated or enzymatically modified samples, competing sugars, lectin omission, antibody omission, matrix blanks, spike-recovery designs, or alternative lectins. The specific control set follows the glycan hypothesis and sample type. The purpose is to determine which part of the signal can be attributed to the target-associated glycan feature.
| Orientation | Where It Can Help | Main Risk | Useful Controls |
|---|---|---|---|
| Antibody capture / lectin detection | Clear target identity and adaptation from an existing target-specific immunoassay | Capture-antibody glycans and masked target glycan motifs | Oxidized or aglycosylated capture reagent, lectin omission, deglycosylated target |
| Lectin capture / antibody detection | Enrichment of a glycan-feature-positive population before target detection | Broad capture of matrix glycoproteins and lower certainty that enrichment is target-specific | Matrix blanks, competing sugar, target-negative material, alternate lectin |
| Competitive lectin-inhibition format | Tests whether lectin occupancy changes antibody detection of a glycoform | Signal can reflect steric interference as well as glycan selectivity | Matched glycoforms, irrelevant lectin, enzymatic glycan modification |
Capture-first designs are often the more controlled starting point for a known target, but lectin-first or inhibition formats may be informative when motif enrichment or accessibility is the central question. Orientation is selected from the target biology and reagent behavior rather than by applying one format to every glycoprotein.
This format is best suited to a defined protein target and a defined lectin-sensitive glycan feature when the main goal is a comparative research readout. For a broader target-associated glycovariant assay strategy, consider glycovariant research assay development. If the decision requires complete glycan structure, linkage, site localization, or occupancy, a glycosylation analysis workflow is more appropriate.
Specify the target protein, glycan feature, sample matrix, study groups, and the conclusion the assay is expected to support.
Assess antibody epitopes, lectin preferences, reagent glycosylation, available standards, expected signal range, and potential background sources.
Establish capture and detection orientation, coating, blocking, incubation, washing, and readout conditions, while incorporating matched negatives, competitors, enzymatic controls, or reagent-only controls as appropriate.
Evaluate representative samples together with dilution behavior, repeatability, spike recovery or parallelism where applicable, matrix effects, and the usable response range.
Summarize selected conditions, pilot results, specificity and reproducibility observations, remaining limitations, and recommended next steps.
A project may begin with customer-supplied reagents, a target and sample set, or only a glycoform hypothesis. Requirements and outputs are defined according to whether the goal is feasibility, orientation selection, optimization, matrix adaptation, or pilot research testing.
Connects lectin selection and epitope accessibility to a biologically meaningful hypothesis.
Defines the starting reagent set and identifies gaps that affect feasibility.
Guides dilution, pretreatment, blocker choice, and interference controls.
Supports pilot design and prevents post hoc interpretation of ambiguous signal.
Clarifies whether the project needs a feasibility report, recommended conditions, or a documented research protocol.
Feasibility findings and the rationale for the selected assay orientation.
Reagent-pair screening data and recommended antibody-lectin combinations when included.
Documented coating, blocking, incubation, washing, and detection conditions generated during the project.
Raw and processed pilot data, control results, and observations on matrix behavior or reproducibility.
A technical report that distinguishes optimized conditions, unresolved limitations, and work that remains necessary before broader use.
A target-linked signal becomes more interpretable when orthogonal controls support the same explanation. Depending on the glycan hypothesis and matrix, useful controls can include deglycosylated or enzymatically modified target, a relevant competitor sugar, target-negative material, lectin omission, antibody omission, matrix blanks, and reagent-background controls. We select the control set to distinguish target-associated glycan signal from capture-reagent, blocker, detection, or matrix effects.
Compare target-associated lectin reactivity across matched research samples.
Test whether a chosen glycan motif on a known protein differs between defined groups.
Evaluate how perturbation, enzyme treatment, or pathway changes alter a target-linked glycan signal.
Determine whether available reagents and sample matrix justify broader assay development.
Ito and colleagues evaluated a lectin-inhibition strategy for distinguishing α2,6-sialylated transferrin from related transferrin glycoforms. In the assay, Sambucus sieboldiana agglutinin (SSA), which recognizes sialylα2,6galactose, reduced antibody binding to native serum transferrin. To test glycan specificity, the authors compared untreated transferrin with periodate-treated Tf, asialo-Tf generated by sialidase digestion, and agalacto-Tf produced by subsequent β-galactosidase treatment. SSA inhibited the signal from α2,6-sialylated serum Tf but not the modified glycoforms, supporting glycan-dependent rather than general inhibition. The extent of inhibition also varied among anti-transferrin antibodies, indicating that antibody epitope position and reagent configuration can influence assay response. These findings illustrate why glycoform-specific assays require matched glycan controls, appropriate lectin selection, and reagent-aware assay design before a signal can be confidently attributed to a particular terminal glycosylation feature.
Please provide the target protein, glycan motif of interest, known glycosylation information, available antibodies and lectins, existing assay conditions, sample matrix, expected abundance, study groups, standards or controls, preferred readout, and whether the immediate goal is feasibility, orientation selection, optimization, or pilot sample testing.
Antibody capture followed by lectin detection is often the more controlled starting point because target identity is established before glycan readout. Lectin capture can help when motif enrichment is needed, but it usually has greater matrix-background risk. The preferred orientation depends on epitope accessibility and reagent behavior.
Most capture antibodies contain Fc glycans that may be recognized by the detection lectin. Background can also come from glycoprotein blockers or secondary reagents. Controls, alternative antibody formats, chemical treatment, or aglycosylated reagents may be considered, depending on the lectin and the intended glycan feature.
No. A lectin-associated signal indicates recognition consistent with the lectin preference under the assay conditions. It does not define the full glycan, linkage, branch, site, or occupancy. Structural assignment generally requires orthogonal glycomics or glycoproteomics methods designed for the specific ambiguity.
Purified proteins, culture supernatants, serum, plasma, tissue extracts, or other research materials may be considered. Matrix suitability depends on target abundance, endogenous glycoproteins, competing substances, and available controls. A pilot dilution and interference assessment is often useful before a larger comparative study.
Not necessarily. Early projects may appropriately end with a feasibility conclusion, preferred orientation, recommended reagent pair, and documented limitations. A more mature project can continue into optimization and pilot testing. The transfer depth is defined before work begins so the deliverable matches the research decision.
Share the target, glycan hypothesis, antibodies, lectins, antigen or standard, sample matrix, expected concentration, current assay information, planned sample contrasts, and intended readout. Creative Biolabs will use these details to identify background risks and an appropriate development depth. For Research Use Only. Not For Clinical Use.
